The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

J. Vardiman; J. Thiele; D. Arber; R. Brunning; M. Borowitz; A. Porwit; N. Harris; M. L. Le Beau; E. Hellström-Lindberg; A. Tefferi; C. Bloomfield

DOI:10.1182/blood-2009-03-209262

Corpus ID: 3101472

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

@article{Vardiman2009The2R,
  title={The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.},
  author={J. Vardiman and J. Thiele and D. Arber and R. Brunning and M. Borowitz and A. Porwit and N. Harris and M. L. Le Beau and E. Hellstr{\"o}m-Lindberg and A. Tefferi and C. Bloomfield},
  journal={Blood},
  year={2009},
  volume={114 5},
  pages={
          937-51
        }
}

J. Vardiman, J. Thiele, +8 authors C. Bloomfield

Published 2009

Medicine

Blood

Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the… CONTINUE READING

View on PubMed

Share This Paper

3,760 Citations

Highly Influencial Citations

185

Background Citations

845

Methods Citations

473

Results Citations

Paper Mentions

OBSERVATIONAL PATIENT REGISTRY CLINICAL TRIAL

Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML

Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a… Expand

Conditions	Acute Myeloid Leukemia

International Consortium on Acute Leukemias

December 2016 - January 2022

OBSERVATIONAL CLINICAL TRIAL

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

An observational, non-interventional, prospective and multicenter study of Azacitidine in newly diagnosed High Risk Myelodysplastic Syndromes. Primary objectives are to asses… Expand

Conditions	Myelodysplastic Syndromes
Intervention	Drug

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

December 2016 - June 2021

INTERVENTIONAL CLINICAL TRIAL

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

This is a multicentre, open-label, randomised phase II trial comparing azacitidine monotherapy with combined azacitidine and vorinostat in patients with newly diagnosed, relapsed… Expand

Conditions	Leukemia, Myeloid, Acute
Intervention	Drug

University of Birmingham

September 2012 - September 2019

OBSERVATIONAL PATIENT REGISTRY CLINICAL TRIAL

Molecular Disease Profile of Hematological Malignancies

In this prospective multicentric study, the University of Pavia together with the Fondazione IRCCS Policlinico San Matteo, Pavia and the IRCCS Fondazione Maugeri, Pavia, Italy will… Expand